In this Issue
A look at some of the promising contenders on the card.
Medical Editors’ Page
By Allen C. Ho, MD, and Robert L. Avery, MD
BUSINESS OF RETINA
Innovations in Retina
Numerous approaches to treatment of dry AMD are under development.
By Aron Shapiro
The surgical training is finished. Now comes the hard part.
By Jayanth Sridhar, MD
Coding for Retina
Recent changes in reimbursement will likely lead to changes in utilization.
By Riva Lee Asbell
Although this procedure can be effective, it should be avoided in eyes with certain characteristics.
By Sergio Rojas, MD, and Ezequiel Diaz Benitez, MD
Clinical findings vary depending on the etiology of the anemia.
By Gaurav Y. Shah, MD, and Rohit Modi, MD
What to look for and how to manage this rare condition.
By Tahreem A. Mir, MD; Marguerite O. Linz; and Ashvini K. Reddy, MD
VVV is typically asymptomatic and benign, but can simulate a life-threatening condition. Know how to tell the difference.
By Michael J. Reynolds, BS; Kareem Sioufi, MD; and Carol L. Shields, MD
SPECIAL FOCUS: RETINAL TRAUMA
A brief history: Part 1.
By Dante J. Pieramici, MD
In this trauma case, temporarily leaving perfluorocarbon liquid in the eye prevented unwanted complications.
By Manish Nagpal, MS, DO, FRCS(Edin)
By William F. Wiley, MD
Gain cooperation from your staff by encouraging them to ask questions and express their concerns.
By Michelle Beckman, JD
COVER FOCUS: THE ONGOING FIGHT AGAINST AMD
A new risk and disease modifier in macular disorders.
By Rosa Dolz-Marco, MD, PhD; Kunal K. Dansingani, MA, FRCOphth; and K. Bailey Freund, MD
Vitreous liquefaction is the cause of many age-related ocular diseases. Figuring out its cause—and how to prevent it—could help to preserve eye health.
By Nancy M. Holekamp, MD
It is crucial to distinguish this entity from neovascular AMD; treatment burden can be reduced if appropriate therapy is applied.
By Jessica G. Shantha, MD, and Gregg T. Kokame, MD, MMM
Promising treatment options under investigation may someday lead to more successful disease management.
By Liliya Golas, MD, and Jeffrey L. Olson, MD
Clinical studies are evaluating a new anti-VEGF agent’s potential to join current treatment options.
By Saradha Chexal, MD; Ivana Gunderson, BS; Brian S. Berger, MD; and Chirag Jhaveri, MD
A device used by patients helps detect early signs of CNV so treatment can be started early.
By Michael J. Elman, MD
Adrienne Scott, MD, is an Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, in Baltimore, Md.